Profile
Henri S.
Lichenstein was the founder of OrphAI Therapeutics, Inc. since 2013, serving as President & Chief Executive Officer until 2021.
Dr. Lichenstein is currently the Chief Executive Officer & Director at Shanghai Drug Farm Biological Technology Co., Ltd. since 2015.
Former positions include Vice President-Product Development at CuraGen Corp.
and Chief Development Officer at Topotarget A.
Henri Lichenstein active positions
| Companies | Position | Start |
|---|---|---|
Shanghai Drug Farm Biological Technology Co., Ltd.
Shanghai Drug Farm Biological Technology Co., Ltd. Information Technology ServicesTechnology Services Develops IDInVivo technology for hepatitis B, cancer and autoimmune diseases | Chief Executive Officer | 2015-10-20 |
Former positions of Henri Lichenstein
| Companies | Position | End |
|---|---|---|
| TOPOTARGET A/S | Corporate Officer/Principal | - |
AI Therapeutics, Inc.
AI Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Chief Executive Officer | 2021-04-30 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology Develops protein, antibody and small molecule pharmaceutical products | Corporate Officer/Principal | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology Develops protein, antibody and small molecule pharmaceutical products | Health Technology |
Topotarget A/S
Topotarget A/S Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceuticals | Health Technology |
AI Therapeutics, Inc.
AI Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Shanghai Drug Farm Biological Technology Co., Ltd.
Shanghai Drug Farm Biological Technology Co., Ltd. Information Technology ServicesTechnology Services Develops IDInVivo technology for hepatitis B, cancer and autoimmune diseases | Technology Services |
- Stock Market
- Insiders
- Henri Lichenstein
















